• Accelero_Autumn_2017_1.jpg
  • Accelero_Autumn_2017_2.jpg
  • Accelero_Autumn_2017_3.jpg
  • Accelero_Autumn_2017_3a.jpg
  • Accelero_Autumn_2017_4.jpg
  • Accelero_Autumn_2017_5.jpg
  • Accelero_Autumn_2017_5a.jpg
  • Accelero_Autumn_2017_7.jpg
  • Accelero_Autumn_2017_8.jpg
  • Accelero_Autumn_2017_9.jpg

Accelerō® Bioanalytics, a newly established Berlin-based bioanalytical contract research organization (CRO) with a strong focus on ligand binding assays compliant to Good Laboratory Practice (GLP), announced today that it has bundled its business into a limited liability company (german: Gesellschaft mit beschränkter Haftung, GmbH). The Accelero Bioanalytics GmbH was registered at the Local Court of Berlin Charlottenburg on December 22nd, 2011 under registration no. HRB 138796 B.

Accelerō® Bioanalytics, a Berlin based contract research organization (CRO) specialized in the development and validation of custom ligand binding assays, announced today that the company´s instrumentation was supplemented by Biotek´s state-of-the-art Synergy 2 multimode plate reader for ultra-sensitive fluorescence, luminescence, and absorbance detection.

Accelerō® Bioanalytics, a recently established contract research organization (CRO) located in the heart of Europe, is pleased to be selected as an associate sponsor for the EuroTIDES 2011 event. This year the well recognized meeting of Europe´s top RNA/DNA drug developers will take place in Berlin, Germany.

The European Medicines Ageny (EMA) announced today that it released a new guideline on the validation of bioanalytical methods applied for quantitative analysis of biological samples collected for pharmacokinetic and toxicokinetic parameter determinations.  The guideline is a continuation of the FDA guidance for industry released 10 years ago, and accommodates the rapidly increasing number of macromolecular drugs pushed to market by the pharmaceutical and biotechnology community.